Kiora Pharmaceuticals (KPRX) Retained Earnings (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Retained Earnings came in at $170.5 million in Q1 2026, up 217.12% YoY from $53.8 million in Q1 2025, and little changed on a QoQ basis from $170.3 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Retained Earnings (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Retained Earnings data on file, last reported at $170.5 million in Q1 2026.
- Quarterly Retained Earnings rose 217.12% year-over-year to $170.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170.5 million (up 217.12% YoY) and the FY2025 annual result came in at $170.3 million, up 0.68% from the prior year.
- Retained Earnings held at $170.5 million in Q1 2026, from $170.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $170.5 million in Q1 2026 to a low of -$145.6 million in Q1 2025.
- A 5-year average of $29.6 million and a median of -$75206.0 in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 220319.24% — and 2025, when it jumped 226256.42%.
- Tracing KPRX's Retained Earnings over 5 years: stood at -$134.5 million in 2022, then jumped by 99.86% to -$182801.0 in 2023, then soared by 92635.8% to $169.2 million in 2024, then climbed by 0.68% to $170.3 million in 2025, then gained by 0.12% to $170.5 million in 2026.
- The last three Retained Earnings figures came in at $170.5 million (Q1 2026), $170.3 million (Q4 2025), and $170.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 4.38 Bn |
| 10 | Kiora Pharmaceuticals | 15.94 Mn | 15.94 Mn | - | 175.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 175.54 Mn |
| Mar 31, 2026 | 170.52 Mn |
| Dec 31, 2025 | 170.31 Mn |
| Sep 30, 2025 | 170.08 Mn |
| Jun 30, 2025 | 169.83 Mn |
| Mar 31, 2025 | -145.60 Mn |
| Dec 31, 2024 | 169.16 Mn |
| Sep 30, 2024 | -75,206.00 |
| Jun 30, 2024 | -135.70 Mn |
| Mar 31, 2024 | -264,374.00 |
| Dec 31, 2023 | -182,801.00 |
| Sep 30, 2023 | 153.00 Mn |
| Jun 30, 2023 | 152.74 Mn |
| Mar 31, 2023 | 146.68 Mn |
| Dec 31, 2022 | -134.46 Mn |
| Sep 30, 2022 | -131.97 Mn |
| Jun 30, 2022 | -126.85 Mn |
| Mar 31, 2022 | -124.44 Mn |
| Dec 31, 2021 | -120.88 Mn |
| Sep 30, 2021 | -59,870.00 |